Latest Breaking News On - Safety monitoring - Page 20 : comparemela.com

 E-Mail New research results for patients with breast and HPV-associated throat cancers are the highlights among 23 presentations by ECOG-ACRIN Cancer Research Group researchers at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, occurring virtually June 4-8. The National Cancer Institute (NCI), part of the National Institutes of Health, funded these studies. Breast Cancer Platinum chemotherapy fails in phase III trial for triple-negative breast cancer, basal-like subtype Abstract 605: About 80% of triple-negative breast cancers (TNBC) are a subtype called basal-like. Typically, patients with TNBC receive chemotherapy before surgery to shrink the tumor(s). The presence of residual cancer in the breast after chemotherapy signals a higher likelihood that the cancer will progress after surgery. A previous clinical trial demonstrated that additional capecitabine chemotherapy after surgery helps decrease the chance of recurrence. Yet, although capecitabine he

United statesJosepha sparanoIngrida mayerRobertl ferrisVered stearnsBreast cancer research foundationMd vanderbilt ingram cancer centerNational cancer instituteAmerican society of clinical oncologyNational institutes of healthCancer research groupSafety monitoring committeeKomen foundationMd johns hopkins universityHillman cancer centerResearch group